<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02154867</url>
  </required_header>
  <id_info>
    <org_study_id>2013/971/REK</org_study_id>
    <nct_id>NCT02154867</nct_id>
  </id_info>
  <brief_title>Fecal Microbial Transplantation in Treatment of Irritable Bowel Syndrome; a Double Blinded Placebo Controlled Trial.</brief_title>
  <acronym>REFIT</acronym>
  <official_title>Recalibrating Intestinal Microflora in IBS by Fecal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of North Norway</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fecal Microbial Transplantation in Treatment of Irritable Bowel Syndrome; a Double Blinded&#xD;
      Placebo Controlled Trial - the REFIT project&#xD;
&#xD;
      Irritable bowel syndrome (IBS) is a condition characterized by variable complaints like&#xD;
      diarrhoea, bloating and abdominal pain, and may result in considerably reduced quality of&#xD;
      life and increased sickness absence. The prevalence of IBS in the general population may be&#xD;
      as high as 15 per cent depending on the diagnostic criteria used. The pathophysiology of IBS&#xD;
      is poorly understood and theories of visceral hypersensitivity, micro-inflammation and other&#xD;
      less well founded theories have been stated. So far, no measurement or test can affirm&#xD;
      diagnosis, but exclusion of organic diseases in combination with a typical symptom pattern&#xD;
      according to the Rome classification can set the diagnosis.&#xD;
&#xD;
      Earlier non-controlled case reports have shown a convincing effect of fecal microbial&#xD;
      transplantation (FMT) in IBS patients. However, no placebo controlled trial has been&#xD;
      performed in this condition. Changes in the gut microbiome may be an important factor in IBS&#xD;
      pathogenesis. Microbiome analysis has revealed changes in microbiome composition that may&#xD;
      trigger changes in visceral sensibility and pain perception.&#xD;
&#xD;
      The fecal microbial transplantation (FMT) procedure has been used primarily to treat&#xD;
      clostridium difficile infections. Few minor side effects have been reported.&#xD;
&#xD;
      Hypothesis: IBS is caused by an imbalance of the gut microbiome that may be reset by&#xD;
      transplanting a microbiome sample from a healthy donor.&#xD;
&#xD;
      Aim of study:&#xD;
&#xD;
        -  To test the clinical effect of FMT in patients with IBS&#xD;
&#xD;
        -  To describe the fecal microbiome in IBS patients&#xD;
&#xD;
        -  To describe changes in the fecal microbiome of IBS patients following FMT&#xD;
&#xD;
      The REFIT study will perform a randomized placebo-controlled double blinded trial of FMT on&#xD;
      IBS according to the Rome 3 criteria. A study group of 60 IBS (diarrhoea variant) patients&#xD;
      will recruited from general practice and allocated to active (30) or placebo (30) by block&#xD;
      randomization. Donors will be 15 healthy volunteers with no risk behaviour and a&#xD;
      pre-screening for communicable diseases will be performed.&#xD;
&#xD;
      Outcome measures will be clinical assessment by IBS-severity scoring system (IBS-SSS) at 0,&#xD;
      1, 3, 6, and 12 months. Microbiome analysis will be performed by metagenomic sequencing&#xD;
      (University of Troms√∏) at 0, 3, and 12 months for patients, and at inclusion for donors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in subjective symptom score</measure>
    <time_frame>at 0 and 3 months</time_frame>
    <description>Comparison of Irritable bowel syndrome severity scoring system (IBS-SSS) grade assessment before and after fecal transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome profile change</measure>
    <time_frame>at 0, 3 and 12 months</time_frame>
    <description>Characterization of fecal microbiome by metagenomic analysis before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term effects of fecal transplantation</measure>
    <time_frame>at 12 months</time_frame>
    <description>Assessment of symptom burden by IBS-SSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of fecal transplantation in IBS</measure>
    <time_frame>during study period (0-12 months)</time_frame>
    <description>Registration of any adverse events. If any serious adverse events are encountered, the study group and local ethics committee will evaluate if study should be terminated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Fecal transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal transplantation of freshly prepared feces from healthy donor. Application by colonoscope in proximal half of colon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo fecal transplantation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham transplant subject's own feces. Application by colonoscope in proximal part of colon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal transplantation</intervention_name>
    <description>Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.</description>
    <arm_group_label>Fecal transplantation</arm_group_label>
    <other_name>Fecal microbial transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo fecal transplant</intervention_name>
    <description>Fecal transplantation with own feces</description>
    <arm_group_label>Placebo fecal transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for patients:&#xD;
&#xD;
          -  Patients with IBS-D according to Roma 3 criteria&#xD;
&#xD;
        Exclusion Criteria for patients:&#xD;
&#xD;
          -  Immunomodulating medication&#xD;
&#xD;
          -  Nocturnal abdominal pain&#xD;
&#xD;
          -  Constant abdominal pain&#xD;
&#xD;
          -  Alarm symptoms like rectal bleeding, weight loss, nightsweats&#xD;
&#xD;
          -  Symptomatic heart/vascular/lung disease&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Known food allergy&#xD;
&#xD;
          -  Microscopic/collagenous colitis&#xD;
&#xD;
          -  non-compliant&#xD;
&#xD;
          -  BMI &lt;18&#xD;
&#xD;
        Inclusion criteria for donors:&#xD;
&#xD;
          -  healthy volunteers&#xD;
&#xD;
        Exclusion criteria for donors&#xD;
&#xD;
          -  Tattoos, imprisoning or piercing last 3 months&#xD;
&#xD;
          -  Any history of chronic diarrhoea, constipation, inflammatory bowel disease, irritable&#xD;
             bowel disease, colorectal polyps or cancer, immunosuppression, morbid obesity,&#xD;
             metabolic syndrome, atopica, or fatigue&#xD;
&#xD;
          -  positive test for hepatitis B, C, HIV, treponema pallidum&#xD;
&#xD;
          -  sexual high risk habits&#xD;
&#xD;
          -  antibiotic treatment in the past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasmus Goll, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of North Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per C Valle, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of North Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Harstad</city>
        <zip>9406</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBS-D</keyword>
  <keyword>FMT</keyword>
  <keyword>metagenomics</keyword>
  <keyword>gut microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

